03.14.19
Rosa & Co. LLC, a drug development advisory firm known worldwide for its PhysioPD Research Platforms, today announced the initiation of a long-term Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd. to provide Rosa's PhysioPD research services.
The collaboration between Chugai and Rosa will provide Chugai a competitive research and development advantage across multiple therapeutic areas and throughout Chugai's R&D pipeline, delivering unique scientific insights and actionable program recommendations, reducing risk and addressing complex and consequential decisions inherent in drug development.
"Chugai strives to develop hand in hand with society through creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation," said Kimio Terao, department manager of the Clinical Pharmacology Department, Translational Research Division, in Chugai.
Rosa's agreement with Chugai further extends Rosa's position as the global market leader in PhysioPD Research, a Quantitative Systems Pharmacology (QSP) approach that translates biology into an interactive simulation platform representing physiology, disease, and intervention effects. It also reinforces the value that PhysioPD Research Platforms deliver through greater scientific insight and more informed drug discovery and development decisions.
The collaboration between Chugai and Rosa will provide Chugai a competitive research and development advantage across multiple therapeutic areas and throughout Chugai's R&D pipeline, delivering unique scientific insights and actionable program recommendations, reducing risk and addressing complex and consequential decisions inherent in drug development.
"Chugai strives to develop hand in hand with society through creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation," said Kimio Terao, department manager of the Clinical Pharmacology Department, Translational Research Division, in Chugai.
Rosa's agreement with Chugai further extends Rosa's position as the global market leader in PhysioPD Research, a Quantitative Systems Pharmacology (QSP) approach that translates biology into an interactive simulation platform representing physiology, disease, and intervention effects. It also reinforces the value that PhysioPD Research Platforms deliver through greater scientific insight and more informed drug discovery and development decisions.
"We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings," said Rosa founder, chairman, & chief executive officer Ron Beaver, PhD. "Our Strategic Research Agreements are a particularly efficient means to achieve the benefits of PhysioPD Research on a portfolio-wide basis."